202 related articles for article (PubMed ID: 18762932)
1. No clinically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volunteers.
Mueller SC; Majcher-Peszynska J; Mundkowski RG; Uehleke B; Klammt S; Sievers H; Lehnfeld R; Frank B; Thurow K; Kundt G; Drewelow B
Eur J Clin Pharmacol; 2009 Jan; 65(1):81-7. PubMed ID: 18762932
[TBL] [Abstract][Full Text] [Related]
2. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose.
Mueller SC; Majcher-Peszynska J; Uehleke B; Klammt S; Mundkowski RG; Miekisch W; Sievers H; Bauer S; Frank B; Kundt G; Drewelow B
Eur J Clin Pharmacol; 2006 Jan; 62(1):29-36. PubMed ID: 16341856
[TBL] [Abstract][Full Text] [Related]
3. Hyperforin in St. John's wort drug interactions.
Madabushi R; Frank B; Drewelow B; Derendorf H; Butterweck V
Eur J Clin Pharmacol; 2006 Mar; 62(3):225-33. PubMed ID: 16477470
[TBL] [Abstract][Full Text] [Related]
4. Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John's Wort.
Adiwidjaja J; Boddy AV; McLachlan AJ
Clin Pharmacokinet; 2019 Jul; 58(7):911-926. PubMed ID: 30675694
[TBL] [Abstract][Full Text] [Related]
5. Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John's wort.
Gödtel-Armbrust U; Metzger A; Kroll U; Kelber O; Wojnowski L
Naunyn Schmiedebergs Arch Pharmacol; 2007 Aug; 375(6):377-82. PubMed ID: 17593354
[TBL] [Abstract][Full Text] [Related]
6. St. John's wort extract with a high hyperforin content does not induce P-glycoprotein activity at the human blood-brain barrier.
El Biali M; Wölfl-Duchek M; Jackwerth M; Mairinger S; Weber M; Bamminger K; Poschner S; Rausch I; Schindler N; Lozano IH; Jäger W; Nics L; Tournier N; Hacker M; Zeitlinger M; Bauer M; Langer O
Clin Transl Sci; 2024 May; 17(5):e13804. PubMed ID: 38700454
[TBL] [Abstract][Full Text] [Related]
7. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures.
Komoroski BJ; Zhang S; Cai H; Hutzler JM; Frye R; Tracy TS; Strom SC; Lehmann T; Ang CY; Cui YY; Venkataramanan R
Drug Metab Dispos; 2004 May; 32(5):512-8. PubMed ID: 15100173
[TBL] [Abstract][Full Text] [Related]
8. Hyperforin contributes to the hepatic CYP3A-inducing effect of Hypericum perforatum extract in the mouse.
Cantoni L; Rozio M; Mangolini A; Hauri L; Caccia S
Toxicol Sci; 2003 Sep; 75(1):25-30. PubMed ID: 12857935
[TBL] [Abstract][Full Text] [Related]
9. Understanding drug interactions with St John's wort (Hypericum perforatum L.): impact of hyperforin content.
Chrubasik-Hausmann S; Vlachojannis J; McLachlan AJ
J Pharm Pharmacol; 2019 Jan; 71(1):129-138. PubMed ID: 29411879
[TBL] [Abstract][Full Text] [Related]
10. Clinical risks of St John's Wort (Hypericum perforatum) co-administration.
Soleymani S; Bahramsoltani R; Rahimi R; Abdollahi M
Expert Opin Drug Metab Toxicol; 2017 Oct; 13(10):1047-1062. PubMed ID: 28885074
[TBL] [Abstract][Full Text] [Related]
11. Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures.
Komoroski BJ; Parise RA; Egorin MJ; Strom SC; Venkataramanan R
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6972-9. PubMed ID: 16203790
[TBL] [Abstract][Full Text] [Related]
12. Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line.
Tian R; Koyabu N; Morimoto S; Shoyama Y; Ohtani H; Sawada Y
Drug Metab Dispos; 2005 Apr; 33(4):547-54. PubMed ID: 15640377
[TBL] [Abstract][Full Text] [Related]
13. Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction.
Mai I; Bauer S; Perloff ES; Johne A; Uehleke B; Frank B; Budde K; Roots I
Clin Pharmacol Ther; 2004 Oct; 76(4):330-40. PubMed ID: 15470332
[TBL] [Abstract][Full Text] [Related]
14. Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers.
Schulz HU; Schürer M; Bässler D; Weiser D
Arzneimittelforschung; 2005; 55(10):561-8. PubMed ID: 16294501
[TBL] [Abstract][Full Text] [Related]
15. Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity.
Fuchs I; Hafner-Blumenstiel V; Markert C; Burhenne J; Weiss J; Haefeli WE; Mikus G
Eur J Clin Pharmacol; 2013 Mar; 69(3):507-13. PubMed ID: 22968811
[TBL] [Abstract][Full Text] [Related]
16. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.
Wang Z; Gorski JC; Hamman MA; Huang SM; Lesko LJ; Hall SD
Clin Pharmacol Ther; 2001 Oct; 70(4):317-26. PubMed ID: 11673747
[TBL] [Abstract][Full Text] [Related]
17. Short term treatment with St. John's wort, hypericin or hyperforin fails to induce CYP450 isoforms in the Swiss Webster mouse.
Bray BJ; Brennan NJ; Perry NB; Menkes DB; Rosengren RJ
Life Sci; 2002 Feb; 70(11):1325-35. PubMed ID: 11883710
[TBL] [Abstract][Full Text] [Related]
18. Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity.
Hafner V; Jäger M; Matthée AK; Ding R; Burhenne J; Haefeli WE; Mikus G
Clin Pharmacol Ther; 2010 Feb; 87(2):191-6. PubMed ID: 19924124
[TBL] [Abstract][Full Text] [Related]
19. The recovery time-course of CYP3A after induction by St John's wort administration.
Imai H; Kotegawa T; Tsutsumi K; Morimoto T; Eshima N; Nakano S; Ohashi K
Br J Clin Pharmacol; 2008 May; 65(5):701-7. PubMed ID: 18294328
[TBL] [Abstract][Full Text] [Related]
20. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects.
Dresser GK; Schwarz UI; Wilkinson GR; Kim RB
Clin Pharmacol Ther; 2003 Jan; 73(1):41-50. PubMed ID: 12545142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]